DrugInformations.org

UroToday.com- The TAX 327 study was reported in 2004 and evaluated patients with hormone-refractory prostate cancer (HRPC) in three treatment arms; docetaxel 75mg/m2 every 3 weeks (D3P), docetaxel 30mg/ m2 weekly (D1P), or mitoxantrone 12 m2 every 3 weeks (MP), each with prednisone 5mg twice daily. It demonstrated significant survival benefit to D3P compared to MP but no significant difference to D1P. D3P also had better palliation. At that report, 557 of 1,006 participants had died.

More: continued here

No Comments »

Tekturna HCT (aliskiren and hydrochlorothiazide) has been approved by the US Food and Drug Administration as a single-tablet combination of two high blood pressure medicines Tekturna (aliskiren), the first new type of high blood pressure medicine in more than a decade, and the diuretic hydrochlorothiazide (HCT)[1].

More: continued here

No Comments »

The independence of children with autism depends on their receiving treatment in natural settings. One of the main problems they face is their inability to learn how to safely cross the street, a necessary skill for independent living. While acquiring this skill could greatly improve these children’s independence, most of the methods for teaching street-crossing have been designed for use within the classroom, and they have been shown as insufficiently effective among autistic children.

More: continued here

No Comments »

Sequenom, Inc. (NASDAQ:SQNM) announced the approval of a protocol by the Institutional Review Board (IRB) at San Diego-based Sharp HealthCare, clearing the way to commence patient enrollment in a screening study to clinically assess the Company’s noninvasive cell free fetal nucleic acid SEQureDx? Technology for the detection of fetal aneuploidy, including Down syndrome, using a laboratory developed test (LDT). More than 2.

More: continued here

No Comments »

The UK’s Human Fertilisation and Embryology Authority (HFEA) has given two UK research projects one year licences to create embryos made of human DNA and animal eggs. The two licenses have been granted to King’s College London and Newcastle University.The researchers want to make stem cells so they can investigate a range of human diseases.

More: continued here

No Comments »

CMS on Tuesday issued a proposed 2.6% payment rate change in 2009 for long-term care hospitals, CQ HealthBeat reports.

More: continued here

No Comments »

Virulite, LLC, a medical device manufacturer dedicated to developing the market for an innovative new treatment for cold sores, announced that it has retained Compass Point Capital, Inc. and Murphy Business and Financial Corporation as its mergers and acquisitions advisors. Virulite, LLC has validated the US market for the Virulite device by successfully completing clinical trials and is presently in the process of obtaining FDA clearance.

More: continued here

No Comments »

While a man with localized prostate cancer will live longer if he receives male hormone suppression therapy combined with radiation treatment, the same does not happen for patients with moderate/high levels of other illnesses, says an article in the Journal of the American Medical Association (JAMA), January 23rd issue.

More: continued here

No Comments »

Being resistant to aspirin makes patients four times more likely to suffer a heart attack, stroke or even die from a pre-existing heart condition, according to a study published on bmj.com. The study relates to patients who are prescribed aspirin long term as a way of preventing clots from forming in the blood.

More: continued here

No Comments »

Australian scientists are researching a possible way of making aggressive prostate cancer cells less invasive after their discovery of a protein essential for the normal functioning of cells. Professor Robert Parton led a team of scientists from the

More: continued here

No Comments »